Compare Lucid Group Inc (LCID) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lucid Group Inc vs Eli Lilly And Co — how do they compare? Lucid Group Inc trades at $3.8 (market cap $1.51B), while Eli Lilly And Co trades at $1,177.77 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 688.7× Lucid Group Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Lucid Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lucid Group Inc for 45 Days and Eli Lilly And Co for 93 Days on average.
| LCID | LLY | |
|---|---|---|
Market Cap | $1.51B | $1.04T |
Volume | 12,333,745 | 3,064,878 |
Sector | Consumer Cyclical | Health |
52-Week High | $21.92 | $1.28K |
52-Week Low | $3.82 | $799.57 |
Typical Hold Time | 45 Days | 93 Days |
Enterprise Value | $4.40B | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lucid Group (LCID) trades at $3.79, down 2.57% on the day, reflecting ongoing investor concerns about the company's financial performance. The stock shows bearish technical signals with negative moving averages and faces fundamental challenges including significant losses, negative profit margins, and cash burn. Recent news highlights management's focus on cost savings and strategic partnerships while delaying key product launches like the Cosmos SUV.
The outlook remains challenging with persistent losses and high cash burn requiring additional financing. Analyst consensus is cautious with only 13% buy ratings and a $7.60 price target representing potential upside. Key risks include execution delays, competitive pressure, and potential dilution from future capital raises.
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
